

Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format along with a portrait photo in JPEG format, if you would like it to accompany your press release, no later than three weeks prior to your defence.

Basic information

Name: Line Kibsgaard Email: lk@clin.au.dk Phone: 22 32 80 96

Department of: Clinical Medicine

Main supervisor: Dr. Christian Vestergaard

Title of dissertation: "Survival, Frequency and Comorbidities of two Rare Skin Diseases: Bullous Pemphigoid and Mastocytosis"

Date for defence: 20/11, 2017 at (time of day): 14-16 Place: Auditoriet, Bygn. 12, MH, P.P. Ørumsgade 11, 8000 Aarhus C

Press release (Danish)

Dermato-epidemiologiske undersøgelser ændrer standard-praksis for håndtering af sjældne hudsygdomme

Nyt PhD-projekt fra Aarhus Universitet giver anledning til skærpet opmærksomhed på følgesygdomme, som ligger i forlængelse af, eller går forud for, diagnosen bulløs pemphigoid. "Uafhængigt af køn og alder har vi påvist en tydelig sammenhæng imellem bulløs pemphigoid og multipel sklerose" udtaler Line Kibsgaard, som forsvare sine forskningsresultater ved en offentlig forelæsning mandag d. 20. November, 2017.

Forskere ved hud- og kønssygdomme, Aarhus har beskrevet 7 års erfaring med lægemidlet Azathioprin som steroid-besparende behandlingsvalg af patienter med moderat til svær bulløs pemphigoid. I selvsamme undersøgelse fandt man en bemærkelsesværdig høj forekomst af hjertekar-sygdomme og nerve-sygdomme, hvorefter en landsdækkende undersøgelse blev iværksat. I dag er Line Kibsgaard ikke i tvivl: "Resultaterne er forholdsvis entydige, og vi anbefaler at den fremtidige håndtering af bulløs pemphigoid patienter indebærer en grundig neurologisk forhistorie (anfaldsvise syns- muskel- føle eller balanceforstyrrelser) lige så vel som risikofaktorer for hjertekar-sygdom bør afdækkes".

"Vores andet studie-design, har høstet international anerkendelse, og vi har valgt at videreføre metoden til endnu en sjælden hudsygdom, nemlig mastocytose. Resultaterne er lige på trapperne og interesserede tilhørere er mere end velkomne til at deltage i den samlede offentliggørelse af alle resultater, som finder sted d. 20. November, 2017, kl. 14-16, i Auditoriet (Bygning 12), Marselisborg Centret, P.P. Ørumsgade 11, 8000 Aarhus C" Titlen på projektet er "Survival, frequency and comorbidity of two rare skin diseases: Bullous Pemphigoid and Mastocytosis". Yderligere oplysninger: Ph.d.-studernde Line Kibsgaard, e-mail: lk@clin.au.dk, tlf. 22 32 80 96.

Bedømmelsesudvalget består af: Lektor Raimar W. Thomsen, MD, MHD (Formand)
Klinisk Epidemiologisk Afdeling, Aarhus Universitets Hospital, Aarhus, Danmark.
Lektor Sebastian Barbarot, MD, PhD, Dermatologisk Afdeling, Nantes Universitets Hospital, Nantes, Frankrig og Lektor Åke Svensson, MD, PhD Dermatologisk Afdeling, Lund Universitet, Malmö Hospital, Malmö, Sverige

Press release (English)

Results from dermatoeidemiological studies changes standard-procedures in the management of rare skindisorder.

Results from a Danish PhD dissertation (Aarhus University) encourage physicians to be aware of specific comorbidities as a consequence to a diagnosis of bullous pemphigoid. "Independent of age and gender, we discovered a significant association between bullous pemphigoid on one hand and multiple sclerosis on the other hand" says Line Kibsgaard, who is defending her dissertation on 20 November, 2017.

Scientists from the department of Dermato-venereology, Aarhus has released their seven years of experience treating bullous pemphigoid patients with Azathioprine as their first choice of a steroid-sparing strategy. Furthermore, the prevalence of cardiovascular and neurological disorders among bullous pemphigoid patients were remarkable. Hence, a national investigation was initiated. Today, Dr. Kibsgaard does not hesitate to state that "Bullous Pemphigoid and multiple Sclerosis are obviously related, based on the relatively unequivocalness of our results. We strongly suggest that future investigations of bullous pemphigoid patients includes a thorough history of previous neurological symptoms such as periodic visual or muscular disturbances. Also, all cardiovascular riskfactors should be assessed.

Our second study design was highly recognized by the international readers. Therefore, similar methods were passed on to the investigations of secondary rare skindisorder: mastocytosis, that is. These results are currently under review and will be presented as part of the public defence. All listeners, who are interested, are more than welcome to join us on 20 November, 2017, at time: 14-16, in the Auditorium (Building 12), Marselisborg Center, P.P. Oerumsgade 11, 8000 Aarhus C. The title of the project is "Survival, frequency and comorbidity of two rare skin diseases: Bullous Pemphigoid and Mastocytosis". Further information: Ph.d. student Line Kibsgaard, e-mail: lk@clin.au.dk, tlf. +45 2232 8096.

The assessment committee: Associate Professor Raimar W. Thomsen, MD, MHD (chairman)
The Department of Clinical Epidemiology, Aarhus University Hospital, Denmark
Associate Professor Sebastian Barbarot, MD, PhD (consultant)
The Department of Dermatology, Nantes University Hospital, Nantes, France and
Associate Professor (Docent) Åke Svensson, MD, PhD (consultant)
The Department of Dermatology, Lund University, Malmö Hospital, Malmö, Sweden

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases as well as any submitted photo.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.